Skip to NavigationSkip to content

Gilead

Gilead buys Novartis' herpes, flu and cold virus preclinical programmes

Gilead has acquired the rights to three of Novartis’ preclinical antiviral programmes, including investigational compounds with the potential to treat influenza, herpes and human rhinovirus, the virus that causes the common cold.

The deal will see Gilead acquire the exclusive global rights to develop and commercialise novel small molecules against the three undisclosed targets.

The deal will see Novartis receive an upfront payment of an undisclosed amount and up to $291 million in milestone payments on reaching commercial and developmental milestones.

Gilead invests $5.1 billion into Galapagos NV

Gilead has entered into a 10 year partnership with Belgo-Dutch biotech Galapagos NV.

The collaboration will see Gilead invest $5.1 billion in Galapagos. The deal will give Gilead access to Galapagos’ portfolio which includes six molecules in clinical trials, 20 preclinical programmes and a proven drug discovery platform.

Gilead will pay Galapagos $3.95 billion upfront and a further $1.1 billion equity investment which Galapagos will use to expand and accelerate its research and development programmes.

ViiV Healthcare's two drug HIV therapy beats Gilead's three drug treatment in Phase 3 trial

Pfizer and GlaxoSmithKline’s HIV company, ViiV Healthcare, has said its two-drug combo Dovato (dolutegravir and lamuvidine) met its primary endpoint of maintaining viral suppression for 48 weeks in patients who had switched from a three drug cocktail made by Gilead.

Dovato proved successful in supressing HIV for 48 weeks in patients who had previously maintained viral suppression on Gilead’s TAF-containing regimen. Additionally, ViiV said patients did not develop resistance to Dovato.

US Government awarded new patent on preventative HIV drugs PrEP

The Department of Health and Human Services (HHS) has been awarded a new patent on drugs that prevent HIV.

The US Patent office has awarded the US government a patent on drugs derived from HIV drug Tenofovir that inhibit the transmission of HIV.

The new patent may reignite a dispute between the government and PrEP drugmaker Gilead over the rights to PrEP drug Truvada and its successor Descovy.

In May 2019, campaigners called on the government to enforce the CDC’s patents on the use of Truvada as a preventative treatment for HIV.

Gilead signs deal with Nurix Therapeutics worth more than $2.3 billion

Gilead has signed a deal with San Francisco biotech Nurix Therapeutics – a company focused on developing drugs that control levels of the enzyme ubiquitin E3 ligases which are responsible for the breakdown of proteins in human cells.

Dysregulated and/or mutated proteins play a central role in the development and progression of many human diseases. It is hoped that by controlling protein levels Nurix’s technologies will be able to tackle cancer and other challenging diseases.

Gilead inks deal with Canadian antibody discovery firm AbCellera

Gilead has entered into an agreement with Canadian monoclonal antibody discovery firm AbCellera.

The two firms will take part in a cross border collaboration to support the discovery of new therapeutic antibody candidates for infectious diseases.

Under the terms of the agreement AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.

Long-term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer

Published on: 07/06/19

Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer.

In her new role Mercier will join Gilead’s senior leadership team when she takes over the California firm’s commercial operations on July 1.

Mercier, who served with BMS for more than ten years, brings a wealth of experience to the role. The experienced executive holds a degree in Biology from the University of Montreal and an MBA from Concordia University.

Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer

Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer.

In her new role Mercier will join Gilead’s senior leadership team when she takes over the California firm’s commercial operations on July 1.

Mercier, who served with BMS for more than ten years, brings a wealth of experience to the role. The experienced executive holds a degree in Biology from the University of Montreal and an MBA from Concordia University.

Top Ten most popular articles on Pharmafile.com this week

On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week's biggest stories in the pharmaceutical industry.

Top Ten most popular articles on Pharmafile.com this week!

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate lawsuits accused them and others of suppressing competition. While Gilead had sought to retain dominance in the HIV drugs market, Teva was alleged to be at the centre of a conspiracy through which generic drugmakers divided up the market for generic meds.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches